IFRX
Price:
$2.51
Market Cap:
$142.08M
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune dis...[Read more]
Industry
Biotechnology
IPO Date
2017-11-07
Stock Exchange
NASDAQ
Ticker
IFRX
According to InflaRx N.V.’s latest financial reports and current stock price. The company's current Enterprise Value is 116.77M. This represents a change of 75.80% compared to the average of 66.42M of the last 4 quarters.
The mean historical Enterprise Value of InflaRx N.V. over the last ten years is 216.85M. The current 116.77M Enterprise Value has changed 5.28% with respect to the historical average. Over the past ten years (40 quarters), IFRX's Enterprise Value was at its highest in in the March 2019 quarter at 816.62M. The Enterprise Value was at its lowest in in the June 2016 quarter at 0.
Average
216.85M
Median
113.08M
Minimum
35.14M
Maximum
740.49M
Discovering the peaks and valleys of InflaRx N.V. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 2.01%
Maximum Annual Enterprise Value = 740.49M
Minimum Annual Increase = -91.96%
Minimum Annual Enterprise Value = 35.14M
Year | Enterprise Value | Change |
---|---|---|
2023 | 69.36M | -38.66% |
2022 | 113.08M | -24.33% |
2021 | 149.44M | 73.82% |
2020 | 85.98M | 44.40% |
2019 | 59.54M | -91.96% |
2018 | 740.49M | 2.01% |
2017 | 35.14M | -90.18% |
2016 | 357.79M | 4.99% |
The current Enterprise Value of InflaRx N.V. (IFRX) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
110.63M
5-year avg
95.48M
10-year avg
216.85M
InflaRx N.V.’s Enterprise Value is less than Generation Bio Co. (143.59M), greater than Kronos Bio, Inc. (8.15M), less than Erasca, Inc. (710.66M), less than C4 Therapeutics, Inc. (280.63M), less than Edgewise Therapeutics, Inc. (2.76B), greater than Kezar Life Sciences, Inc. (29.92M), less than Fulcrum Therapeutics, Inc. (181.94M), greater than Passage Bio, Inc. (33.76M), greater than Acumen Pharmaceuticals, Inc. (104.35M), greater than Galera Therapeutics, Inc. (-6823234.00), less than Inozyme Pharma, Inc. (210.44M), less than Eledon Pharmaceuticals, Inc. (248.84M), less than Icosavax, Inc. (713.87M), greater than Ocuphire Pharma, Inc. (-9671816.00), greater than Reviva Pharmaceuticals Holdings, Inc. (77.44M), greater than Protalix BioTherapeutics, Inc. (108.61M), less than EyePoint Pharmaceuticals, Inc. (442.37M), greater than SELLAS Life Sciences Group, Inc. (44.97M), less than Monte Rosa Therapeutics, Inc. (351.25M), less than Design Therapeutics, Inc. (331.74M), greater than Werewolf Therapeutics, Inc. (-17421672.00), greater than Ikena Oncology, Inc. (37.04M), less than Stoke Therapeutics, Inc. (451.87M),
Company | Enterprise Value | Market cap |
---|---|---|
143.59M | $71.47M | |
8.15M | $57.32M | |
710.66M | $726.61M | |
280.63M | $273.18M | |
2.76B | $2.80B | |
29.92M | $47.86M | |
181.94M | $245.42M | |
33.76M | $40.24M | |
104.35M | $107.54M | |
-6823234.00 | $1.63M | |
210.44M | $188.22M | |
248.84M | $255.09M | |
713.87M | $769.04M | |
-9671816.00 | $31.74M | |
77.44M | $82.91M | |
108.61M | $130.33M | |
442.37M | $500.28M | |
44.97M | $65.42M | |
351.25M | $433.13M | |
331.74M | $359.54M | |
-17421672.00 | $68.63M | |
37.04M | $73.83M | |
451.87M | $599.59M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like InflaRx N.V. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like InflaRx N.V. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is InflaRx N.V.'s Enterprise Value?
What is the highest Enterprise Value for InflaRx N.V. (IFRX)?
What is the 3-year average Enterprise Value for InflaRx N.V. (IFRX)?
What is the 5-year average Enterprise Value for InflaRx N.V. (IFRX)?
How does the current Enterprise Value for InflaRx N.V. (IFRX) compare to its historical average?